Prolacta Bioscience® Appoints David C. Dreyer Chief Financial Officer

DUARTE, Calif., May 16, 2017 – Prolacta Bioscience, the nation’s leading provider of human milk-based neonatal nutritional products to hospitals, has appointed David C. Dreyer as chief financial officer. Dreyer brings nearly three decades of experience in the fields of biotechnology, pharmaceuticals and medical devices to Prolacta.


“David has a great track record as a leader with a history of integrity and financial accountability,” said Scott Elster, CEO of Prolacta Bioscience. “His proven vision for identifying new business opportunities and growing teams will be key to Prolacta’s continued growth and success. We are very fortunate to have such a highly respected professional join our team, and I’m looking forward to his contributions.”


Dreyer most recently was CFO of BIOLASE, Inc. (NASDAQ: BIOL). There, he helped re-align the company’s infrastructure and led investor financing to help fund future growth. Previously, Dryer served as CFO, COO and secretary for Patient Safety Technologies (OTC: PSTX), a subsidiary of Stryker Corp (NYSE: SYK). Dryer also was CFO for AlphaStaff Group, CFO for AMN Healthcare Services (NYSE: AHS), and has worked for Sicor (formerly NASDAQ: SCRI). He serves on the boards of Diplomat Pharmacy and InfuSystem Holdings (NYSE: INFU). He holds a Bachelor of Science degree in accounting from Golden Gate University, where he graduated magna cum laude. Dryer has been a certified public accountant in the state of California since 1986.


Dreyer replaces longtime Prolacta CFO Tami D. Ciranna, who served the company since 2010. Ciranna announced her planned retirement in October 2016, and has been instrumental in Dreyer’s transition. She continues to consult for the company.

About Prolacta Bioscience

Prolacta Bioscience, Inc. is a privately held life sciences company dedicated to Advancing the Science of Human Milk®. The company pioneered the development of human milk-based neonatal nutritional products to meet the needs of critically ill, premature infants in the neonatal intensive care unit (NICU). Prolacta leads the industry in the quality and safety of nutritional products made from donor breast milk and operates the first and only pharmaceutical-grade manufacturing facility for the processing of human breast milk.